STOCK TITAN

Phibro Animal Health Corporation - PAHC STOCK NEWS

Welcome to our dedicated page for Phibro Animal Health Corporation news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal Health Corporation stock.

Phibro Animal Health Corporation (Class A, symbol: PAHC) is a leading global company specializing in animal health and mineral nutrition. With over 40 years of experience, Phibro is dedicated to meeting the rising demand for animal protein by focusing solely on animals used in food production. The company offers a comprehensive range of products for poultry, swine, beef and dairy cattle, and aquaculture.

Phibro's core business involves the development, manufacturing, and marketing of products designed to prevent, control, and treat animal diseases, enhance nutrition, and contribute to balanced mineral nutrition. Their product portfolio includes antibacterials, anticoccidials, nutritional specialty products, and vaccines. The company's operations are divided into three segments: Animal Health, Mineral Nutrition, and Performance Products, with the Animal Health segment being the primary revenue driver.

In the fiscal year ending June 30, 2017, Phibro reported net sales of $764 million. The company employs over 1,400 professionals who are committed to delivering value-based solutions to livestock producers, helping them maintain and enhance the health of their animals. Phibro's products are sold both in the United States and internationally, demonstrating its significant global footprint.

Recent achievements and ongoing projects by Phibro include the development of new vaccines and nutritional specialties aimed at improving animal health and productivity. The company continues to partner with various stakeholders in the livestock industry to innovate and provide sustainable solutions.

Phibro's financial condition remains robust, supported by consistent revenue streams from its diversified product offerings. The company’s focus on research and development underscores its commitment to advancing animal health technologies and addressing the evolving needs of the livestock industry.

For the latest news and updates, Phibro Animal Health Corporation remains a key player in the animal health sector, reflecting its dedication to enhancing the well-being of food animals globally.

Rhea-AI Summary

Phibro Animal Health (Nasdaq: PAHC) has released its third annual Environmental, Social, and Governance (ESG) Report, highlighting 2023 achievements. The report emphasizes Phibro's commitment to enhancing animal health and nutrition to promote sustainability. Significant efforts include disease prevention, waste reduction, and resource conservation, which contribute to a safer, more affordable food supply. These initiatives align with the UN's 2030 Sustainable Development Goals (SDGs). The report underscores the importance of the One Health approach, emphasizing interconnections among the health of people, animals, and the planet. Phibro’s work in 2023 focused on reducing greenhouse gas emissions, enhancing food production efficiency, and supporting farmers' economic stability. This contributes to mitigating climate change and promoting food security. The company aims to continue driving sustainability and ethical growth, ensuring positive global contributions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
-
Rhea-AI Summary

Phibro Animal Health (Nasdaq: PAHC) announced its participation in the Stifel Annual Dental and Animal Health (Jaws & Paws) Conference.

Key executives including CFO Glenn David, COO Larry Miller, and EVP Corporate Strategy Daniel Bendheim will present to financial analysts and investors on May 29, 2024, at 10:20 AM ET, at the St. Regis New York.

The live audio presentation will be accessible on the Phibro Animal Health Investor Relations Website, with a replay available for later viewing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences
-
Rhea-AI Summary

Phibro Animal Health reported strong financial results for the third quarter, with net sales increasing by 7% and adjusted EBITDA up by 9%. The company affirmed its fiscal year 2024 guidance, including net sales of $980 million to $1.020 billion and adjusted diluted EPS of $1.04 to $1.16. Phibro also updated its guidance for net income and diluted EPS due to recent developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
Rhea-AI Summary

Phibro Animal Health (PAHC) announced a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock, payable on June 26, 2024. The dividend will be distributed to stockholders of record as of June 5, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
dividends
-
Rhea-AI Summary

Zoetis Inc. (NYSE:ZTS) has entered into a definitive agreement with Phibro Animal Health (Nasdaq: PAHC), where the latter will acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products, and related assets for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024. The portfolio, generating approximately $400 million in revenue in 2023, comprises more than 37 product lines sold in around 80 countries, spanning across six manufacturing sites. More than 300 Zoetis colleagues will transition to Phibro Animal Health. The divestiture allows Zoetis to focus its livestock investments in other areas, such as vaccine, biologic, and genetic programs. The acquisition is expected to boost Phibro Animal Health’s sales and profitability significantly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.81%
Tags
none
-
Rhea-AI Summary
Phibro Animal Health (PAHC) will release its third-quarter financial results on May 8, 2024, followed by a conference call and webcast on May 9, 2024. Interested parties can access the call and presentation slides online or via phone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
conferences earnings
Rhea-AI Summary
Phibro Animal Health Corporation (PAHC) will participate in the Barclays Global Healthcare Conference with its CFO and COO presenting to analysts and investors. The event will take place on March 12, 2024, at 4:35 PM ET in Miami Beach. The presentation will be available live and archived on the company's Investor Relations Website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.56%
Tags
conferences
-
Rhea-AI Summary
Phibro Animal Health Corporation (PAHC) to participate in Bank of America 2024 Virtual Animal Health Summit with CFO and EVP Corporate Strategy presenting to financial analysts and investors. The live audio presentation will be on February 29, 2024, at 10:00 AM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
conferences
-
Rhea-AI Summary
Phibro Animal Health Corporation (PAHC) announced its Q2 financial results, showing a 2% increase in net sales to $249.9 million and a 5% decrease in adjusted EBITDA to $29.5 million. The company affirmed its fiscal year 2024 guidance for net sales and adjusted EBITDA, but updated its guidance for net income and diluted EPS, reflecting recent developments such as expenses for Brazil employment taxes and foreign currency losses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.4%
Tags
Rhea-AI Summary
Phibro Animal Health Corporation (PAHC) has declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock, payable on March 27, 2024, to stockholders of record at the close of business on March 6, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
dividends

FAQ

What does Phibro Animal Health Corporation do?

Phibro Animal Health Corporation develops, manufactures, and markets a broad range of animal health and mineral nutrition products for food animals.

Which animals does Phibro's products cater to?

Phibro's products are designed for poultry, swine, beef and dairy cattle, and aquaculture.

What are the main product categories of Phibro Animal Health Corporation?

The main product categories include antibacterials, anticoccidials, nutritional specialty products, vaccines, and mineral nutrition products.

How many employees does Phibro Animal Health Corporation have?

Phibro employs over 1,400 professionals.

How much revenue did Phibro report for the fiscal year ending June 30, 2017?

Phibro reported net sales of $764 million for the fiscal year ending June 30, 2017.

What are the primary segments of Phibro's operations?

Phibro operates through three primary segments: Animal Health, Mineral Nutrition, and Performance Products.

Where does Phibro sell its products?

Phibro sells its products in the U.S. and international markets.

What recent projects is Phibro involved in?

Phibro is involved in developing new vaccines and nutritional specialties aimed at improving animal health and productivity.

Who are Phibro's primary customers?

Phibro's primary customers are livestock producers who use their products to maintain and enhance the health of their animals.

What drives Phibro's revenue?

The Animal Health segment, which includes antibacterials, nutritional specialty products, and vaccines, is the key revenue driver for Phibro.

Phibro Animal Health Corporation

Nasdaq:PAHC

PAHC Rankings

PAHC Stock Data

754.99M
20.34M
0.63%
104.83%
1.14%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
TEANECK